– USA, CA – Senti Biosciences, Inc. (Nasdaq: SNTI), a clinical-stage biotechnology company developing next-generation cell and gene therapies, announced the appointment of Feng Hsiung to its Board of Directors effective March 7, 2025.
“We are pleased to welcome Feng to our Board, He brings deep expertise in investment strategy and capital markets across multiple industries,” said CEO Dr.Timothy Lu. “We look forward to the unique business perspectives he’ll provide to Senti Bio as we execute on our strategic objectives and drive long-term growth.”
Feng Hsiung will also join the Audit Committee.
About Feng Hsiung
Feng Hsiung is the Founder, CIO, and CEO of Acion Partners, an investment advisor firm that has a strategic partnership with KKR and invests across industries. From 2007 through 2014, Mr. Hsiung was a Partner and CEO (Asia) at York Capital. He started its Asia business as the initial employee in 2007 and launched and co-managed the York Asian Opportunities Master Fund. Mr. Hsiung has been a member of the Young Presidents’ Organization since 2013 and the President of Raising Investment Corporation, the holding company for his family’s interests in freight forwarding and contract logistics. Mr. Hsiung holds a B.A. from Dartmouth College.
About Senti Bio
Senti Bio is a clinical-stage biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging a synthetic biology platform called Gene Circuits to create therapies with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, spare healthy cells, increase specificity to target cells, and control the expression of drugs even after administration. Senti Bio’s wholly-owned pipeline includes off-the-shelf CAR-NK cells, outfitted with Gene Circuits, to target challenging liquid and solid tumor indications. Senti Bio’s lead program SENTI-202, a Logic Gated CD33 and/or FLT3-targeting hematologic cancer therapeutic candidate, demonstrated MRD-negative complete remissions in 2 of 3 patients in initial clinical data as of September 19, 2024, with 4+ and 3+ month durability as of December 2, 2024. Senti Bio has also preclinically demonstrated that its Gene Circuits can function in T cells, for example against solid tumor targets. Additionally, Senti Bio has preclinically demonstrated the potential breadth of Gene Circuits in other cell and gene therapy modalities, and diseases outside of oncology, and continues to advance these capabilities through partnerships.
For more: https://www.sentibio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.